

Dr Dube and Greg Fenton on ZEN's potential graphene-based antibiotic, antiviral and antifungal compound

written by InvestorNews | December 29, 2020

In a recent InvestorIntel interview, Peter Clausi speaks with Dr. Francis Dube, Executive Chairman, and Greg Fenton, CEO and Director of [ZEN Graphene Solutions Ltd.](#) (TSXV: ZEN), about ZEN Graphene's potential graphene-based antibiotic, antiviral and antifungal compound which could be a medical breakthrough in the treatment of numerous human-contracted pathogens including COVID-19.

In this InvestorIntel interview, which may also be viewed on YouTube ([click here](#) to subscribe to the [InvestorIntel Channel](#)), Greg went on to say, "We unfortunately had to shut down most of our research and development due to COVID-19." He continued, "Fortunate for us, we had just opened up our own research lab in Guelph. **We joined together with our research partners and tested to see if there was anything we could do to help beat this virus.**"

Dr. Dube told InvestorIntel that ZEN Graphene has already filed patent for a graphene-based virucidal ink to be used in masks, PPE and the HVAC (Heating, ventilation, and air conditioning) sector. He added that the company is now exploring graphene's use in the fight against the current global pandemic.

On December 22, 2020, ZEN Graphene Solutions [announced](#) that it had developed a potential graphene-based antibiotic, antiviral and antifungal compound. Commenting on this news release Greg

said, “The versatility of this product is way beyond anything even we could have imagined. Not only the range of pathogens that it is effective against, but how it can be deployed and utilized. **It went from us simply talking about bringing our product into coating, to us talking about actually bringing it into the body.**”

To watch the full interview, [click here](#)

About ZEN Graphene Solutions Ltd.

ZEN is a graphene technology solutions company with a focus on the development of graphene based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a potential competitive advantage in the graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN’s Albany Pure™ Graphite is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods. ZEN is focused on commercializing a patent pending graphene-based coating with 99% viricidal activity against

To learn more about ZEN Graphene Solutions Ltd., [click here](#)

ZEN Graphene Disclaimer: The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. The company must receive Health Canada or FDA approvals for any of the products or solutions discussed.

InvestorIntel Disclaimer: ZEN Graphene Solutions Ltd. is an advertorial member of InvestorIntel Corp.